STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLNO
  4. [Form 4] SOLENO THERAPEUTICS INC Insider Trading Activity

Soleno Therapeutics (SLNO) CEO adds RSUs and 131,400 stock options in Form 4

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported new equity awards in the form of restricted stock units and stock options. On January 21, 2026, he received 114,200 shares of Common Stock at $0 cost, identified in the footnotes as restricted stock units (RSUs) that each represent a right to one share of Common Stock. These RSUs are scheduled to vest 100% on December 15, 2027, as long as he continues as a service provider under the company’s 2014 Equity Incentive Plan.

On the same date, Bhatnagar was granted an employee stock option covering 131,400 shares of Common Stock at an exercise price of $43.65 per share. The option begins vesting on February 1, 2026, with 1/48th of the shares vesting on that date and on each monthly anniversary thereafter, subject to continued service. After these transactions, he directly held 583,656 shares of Common Stock and 131,400 derivative securities (stock options).

Positive

  • None.

Negative

  • None.
Insider Anish Bhatnagar
Role CHIEF EXECUTIVE OFFICER
Type Security Shares Price Value
Grant/Award Employee stock option (right to buy) 131,400 $0.00 --
Grant/Award Common Stock 114,200 $0.00 --
Holdings After Transaction: Employee stock option (right to buy) — 131,400 shares (Direct); Common Stock — 583,656 shares (Direct)
Footnotes (1)
  1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Anish Bhatnagar
(Last) (First) (Middle)
100 MARINE PARKWAY, SUITE 400
(Street)
REDWOOD CITY CA 94065
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2026 A 114,200(1) A $0 583,656(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy) $43.65 01/21/2026 A 131,400 (3) 01/21/2036 Common Stock 131,400 $0 131,400 D
Explanation of Responses:
1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.
2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
/s/ Anish Bhatnagar 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Soleno Therapeutics (SLNO) report for Anish Bhatnagar on January 21, 2026?

On January 21, 2026, Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported two equity awards: an employee stock option for 131,400 shares of Common Stock at an exercise price of $43.65 per share, and an award of 114,200 shares of Common Stock at $0 per share, described in the footnotes as restricted stock units (RSUs).

How many Soleno Therapeutics (SLNO) shares does Anish Bhatnagar own after these Form 4 transactions?

Following the reported transactions, Anish Bhatnagar directly beneficially owned 583,656 shares of Soleno Therapeutics Common Stock and 131,400 derivative securities in the form of stock options, as disclosed in the Form 4.

What are the vesting terms of the RSUs granted to the Soleno (SLNO) CEO?

The filing explains that the 114,200 securities are restricted stock units (RSUs), each representing a right to receive one share of Common Stock. 100% of these RSUs vest on December 15, 2027, provided Anish Bhatnagar continues to be a service provider under Soleno’s 2014 Equity Incentive Plan through that date.

What are the vesting terms of the 131,400 Soleno (SLNO) stock options reported in the Form 4?

The employee stock option covering 131,400 shares of Common Stock vests monthly. According to the footnote, 1/48th of the shares vest on February 1, 2026, and 1/48th vest on each one-month anniversary thereafter, conditioned on continued service as a provider under the 2014 Equity Incentive Plan.

At what price can the Soleno (SLNO) CEO exercise the newly granted stock options?

The employee stock option reported in the Form 4 has an exercise price of $43.65 per share of Soleno Therapeutics Common Stock, as disclosed in the derivative securities table.

Are the Soleno Therapeutics (SLNO) RSUs and options held directly or indirectly by the CEO?

The Form 4 indicates that both the Common Stock holdings (including RSUs) and the employee stock option are held with direct (D) ownership by Anish Bhatnagar, with no indirect ownership entity listed in the nature-of-ownership field.